Cover Image

BRAF mutation in hairy cell leukemia

Ahmad Ahmadzadeh, Saeid Shahrabi, Kaveh Jaseb, Fatemeh Norozi, Mohammad Shahjahani, Tina Vosoughi, Saeideh Hajizamani, Najmaldin Saki
  • Ahmad Ahmadzadeh
    Health Research Institute, Research Center of Thalassemia and Hemoglobinopathy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran, Islamic Republic of
  • Saeid Shahrabi
    Department of Biochemistry and Hematology, Semnan University of Medical Sciences, Semnan, Iran, Islamic Republic of
  • Kaveh Jaseb
    Health Research Institute, Research Center of Thalassemia and Hemoglobinopathy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran, Islamic Republic of
  • Fatemeh Norozi
    Health Research Institute, Research Center of Thalassemia and Hemoglobinopathy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran, Islamic Republic of
  • Mohammad Shahjahani
    Health Research Institute, Research Center of Thalassemia and Hemoglobinopathy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran, Islamic Republic of
  • Tina Vosoughi
    Health Research Institute, Research Center of Thalassemia and Hemoglobinopathy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran, Islamic Republic of
  • Saeideh Hajizamani
    Health Research Institute, Research Center of Thalassemia and Hemoglobinopathy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran, Islamic Republic of
  • Najmaldin Saki
    Health Research Institute, Research Center of Thalassemia and Hemoglobinopathy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran, Islamic Republic of | najmaldinsaki@gmail.com

Abstract

BRAF is a serine/threonine kinase with a regulatory role in the mitogen-activated protein kinase (MAPK) signaling pathway. A mutation in the RAF gene, especially in BRAF protein, leads to an increased stimulation of this cascade, causing uncontrolled cell division and development of malignancy. Several mutations have been observed in the gene coding for this protein in a variety of human malignancies, including hairy cell leukemia (HCL). BRAF V600E is the most common mutation reported in exon15 of BRAF, which is observed in almost all cases of classic HCL, but it is negative in other B-cell malignancies, including the HCL variant. Therefore it can be used as a marker to differentiate between these B-cell disorders. We also discuss the interaction between miRNAs and signaling pathways, including MAPK, in HCL. When this mutation is present, the use of BRAF protein inhibitors may represent an effective treatment. In this review we have evaluated the role of the mutation of the BRAF gene in the pathogenesis and progression of HCL.

Keywords

BRAF mutation, MAPK signaling pathway, hairy cell leukemia, miRNA.

Full Text:

PDF
HTML
Submitted: 2014-05-04 19:48:10
Published: 2014-09-23 18:03:37
Search for citations in Google Scholar
Related articles: Google Scholar
Abstract views:
2109

Views:
PDF
533
HTML
2139

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM


Copyright (c) 2014 Ahmad Ahmadzadeh, Saeid Shahrabi, Kaveh Jaseb, Fatemeh Norozi, Mohammad Shahjahani, Tina Vosoughi, Saeideh Hajizamani, Najmaldin Saki

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 
© PAGEPress 2008-2017     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185